EUCTR2014-002987-34-DE进行中（未招募）不适用
A Phase 2, Randomized, Double-Blind Study of Ipilimumab Administered at 3 mg/kg vs 10 mg/kg in Adult Subjects with Metastatic Chemotherapy-Naïve Castration Resistant Prostate Cancer Who are Asymptomatic or Minimally SymptomaticPharmacogenetics Blood Sample Amendment Number 01
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 250
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •- Prostate cancer with metastases
- •- Prostate cancer should be castration resistant
- •- Progression during hormonal therapy
- •Please see protocol for further information on inclusion criteria
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 75
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 175
排除标准
- •- Visceral metastases (eg liver, lung or brain metastases)
- •- Prior treatment with any immunotherapy for prostate cancer
- •- Prior or ongoing cytotoxic therapy for prostate cancer
- •- Autoimmune disease
- •- Inadequate hematologic, renal, or hepatic function
- •Please see protocol for further information on exclusion criteria
研究者
相似试验
已完成
2 期
A Phase 2, Randomized, Double-Blind Study of Ipilimumab Administered at 3 mg/kg vs 10 mg/kg in Adult Subjects with Metastatic Chemotherapy-Naïve Castration Resistant Prostate Cancer Who are Asymptomatic or Minimally Symptomatic;Pharmacogenetics Blood Sample Amendment Number 01NL-OMON42128Bristol-Myers Squibb18
进行中（未招募）
1 期
Safety and Efficacy study of ipilimumab 3 mg/kg versus ipilimumab 10 mg/kg in subjects with metastatic castration resistant prostate cancer who are chemotherapy naiveMetastatic Chemotherapy-Naïve Castration Resistant Prostate CancerMedDRA version: 17.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-002987-34-GBBristol-Myers Squibb International Corporation82
进行中（未招募）
1 期
Safety and Efficacy study of ipilimumab 3 mg/kg versus ipilimumab 10 mg/kg in subjects with metastatic castration resistant prostate cancer who are chemotherapy naiveEUCTR2014-002987-34-ITBristol-Myers Squibb International Corporation250
进行中（未招募）
1 期
Safety and Efficacy study of ipilimumab 3 mg/kg versus ipilimumab 10 mg/kg in subjects with metastatic castration resistant prostate cancer who are chemotherapy naiveMetastatic Chemotherapy-Naïve Castration Resistant Prostate CancerMedDRA version: 17.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-002987-34-ESBristol-Myers Squibb International Corporation250
进行中（未招募）
1 期
Safety and Efficacy study of ipilimumab 3 mg/kg versus ipilimumab 10 mg/kg in subjects with metastatic castration resistant prostate cancer who are chemotherapy naiveMetastatic Chemotherapy-Naïve Castration Resistant Prostate CancerMedDRA version: 17.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-002987-34-NLBristol-Myers Squibb International Corporation250